Morlaix

In recent years, the sport of foiling has rapidly grown, especially among amateur sailors. Foiling involves the use of a foil-equipped craft that allows greater speed and height, which may increase the risk of accidents and injuries. However, there is limited research on the impact of foiling on water-related injuries. This study aims to compare the number and types of injuries sustained during water sports involving foils versus those without foils, as well as to analyze patient care related to these injuries. The study will observe patients who have suffered boating accidents, focusing on whether foil-equipped crafts were involved. It will compare injury distributions and management practices between those injured while foiling and those injured in other water sports. There are no specific treatments or interventions applied as part of this observational study. Participants will be patients who have visited an emergency room within seven days of a boating accident. They will be asked to complete a questionnaire about their accident and injury. Researchers will evaluate the importance of foil-equipped crafts in causing water-related injuries over a 12-month period. The study aims to improve anticipation and management of patients injured during these water sports.

Researchers are studying the biological features of advanced ALK-rearranged non-small cell lung cancer (NSCLC) in patients treated with new generation tyrosine kinase inhibitors (TKIs) as their first therapy. This study is part of the national EXPLORE ALK cohort, a multi-center observational project in France, focusing on patients with this specific genetic alteration. The goal is to better understand the tumor biology and resistance mechanisms by analyzing samples from diagnosis through disease progression. The study collects tumor tissue samples at diagnosis and, when possible, at disease progression for RNA sequencing to identify ALK fusion partners, variants, and co-mutations. Blood samples are also taken at diagnosis, first tumor evaluation, and at progression to analyze circulating tumor DNA (ctDNA) using next-generation sequencing panels that detect mutations, fusions, and other genetic changes. These biological analyses are centralized at specialized centers such as the Léon Bérard Center and Rouen University Hospital. Patients are treated with approved ALK inhibitors like alectinib, brigatinib, lorlatinib, or entrectinib as part of their standard care. Participants will provide blood samples at multiple time points and, if possible, tumor biopsy samples for detailed genetic analysis. Researchers will monitor the progression-free survival from treatment start for up to 72 months. The study involves regular evaluations to assess tumor status and collect biological material to track genetic changes over time. Consent for sample collection and participation in the study is required, and patient data is managed within the national health system framework.

Researchers are studying Philadelphia-negative myeloproliferative neoplasms (MPN), which include Polycythemia Vera (PV), essential thrombocythemia (ET), and prefibrotic myelofibrosis (PreMF). These chronic blood cancers involve specific mutations like JAK2V617F and carry a high risk of blood clots that can cause serious health problems. Current treatments include low-dose aspirin to reduce arterial clots, but patients still face risks of thrombosis and bleeding. This trial explores whether direct oral anticoagulants (DOACs), such as Apixaban or Rivaroxaban, might better prevent these clotting events in patients with the JAK2V617F mutation. Participants will be randomly assigned to receive either a DOAC (Apixaban 2.5 mg twice daily or Rivaroxaban 10 mg once daily) or low-dose aspirin (100 mg once daily). The study focuses on high-risk MPN patients with JAK2V617F mutation and will compare the effectiveness and safety of DOACs versus aspirin for preventing blood clots. Treatment will continue with close monitoring throughout the study. During the study, researchers will track the time until any arterial or venous blood clots occur over a 24-month follow-up period. Participants will undergo regular assessments to monitor clotting events, bleeding risks, and overall health. The trial aims to gather detailed information on how well these treatments prevent thrombosis and their safety profiles, helping to guide future care for patients with these blood disorders.

Researchers are studying adults with community-acquired pneumonia who need oxygen therapy due to acute respiratory failure meeting acute respiratory distress syndrome (ARDS) criteria. This condition often leads to tracheal intubation and poor outcomes. Previous studies showed that prone positioning reduces mortality in invasively ventilated ARDS patients and improves oxygenation in non-intubated patients with viral pneumonia, including COVID-19 cases. This trial focuses on patients with non-COVID community-acquired pneumonia using nasal high flow therapy, aiming to see if awake prone positioning can reduce the need for intubation and related treatments like sedation and muscle relaxation. Participants will be encouraged to spend as much time as possible in the prone position, ideally 4 to 8 hours per session, with a goal of up to 16 hours or more within each 24-hour period, depending on their tolerance. This intervention is compared to usual care without prone positioning. The study excludes patients with recent COVID-19 infection or those requiring immediate intubation. During the study, researchers will monitor patients for up to 28 days after randomization, focusing on whether they require intubation. Participants will be admitted to an intensive care or intermediate care unit, and their oxygen levels will be closely assessed using the PaO2/FiO2 ratio or equivalent SpO2/FiO2 measurements. Consent and social security affiliation are required. Safety and effectiveness of awake prone positioning in reducing intubation needs will be evaluated throughout the study period.

Vestibular neuritis is a sudden and intense dizziness caused by inflammation of the nerve connecting to the vestibular canals in the inner ear. It leads to prolonged vertigo, balance problems, nausea, and vomiting without hearing loss or other neurological symptoms. This condition is a common cause of peripheral vertigo, and this research aims to see if wearing Boarding Ring glasses can help speed up recovery of balance in affected adults. Participants will be studied to compare the effects of Boarding Ring glasses against placebo glasses or no glasses. Diagnostic tests used include caloric tests involving warm and cold water in the ear to stimulate the vestibular system, measurements of eye movements with infrared cameras, and assessment of body rotation during stepping tests. Questionnaires about balance-related disability, vertigo symptoms, and anxiety levels will also be completed. Throughout the 7-day study, participants will be monitored using several tests to measure changes in vestibular function and balance, such as the angle of deviation during the Fukuda test. Researchers will assess improvement by comparing these measures from the start to day 7. The study also tracks eye movement response, degree of nystagmus, and questionnaires to evaluate vertigo impact and anxiety, ensuring a comprehensive evaluation of treatment effects and safety.

Researchers are evaluating whether using electrodialyzed seawater can shorten the duration of symptoms in infants with acute bronchiolitis, compared with standard saline solution. This multicenter, prospective, randomized, double-blind study involves infants aged 1 month to under one year experiencing their first episode of mild to moderate acute bronchiolitis with nasal obstruction. The study aims to measure the time it takes for symptoms to resolve over a 10-day period. Participants are randomly assigned to one of two groups: one group receives electrodialyzed seawater (Physiomer) and the other receives saline solution. Both treatments are administered by parents at home for up to 10 days with dosing adjusted by age and discomfort. Infants under 6 months receive half to full doses per nostril eight times daily, while those over 6 months receive one dose per nostril six times daily. The study is double-blinded to ensure unbiased results. During the study, parents will be contacted by phone on days 1, 3, 6, 10, and 21 after starting treatment to monitor progress and safety. The main measure is how quickly the infants recover from bronchiolitis symptoms, assessed daily through day 10. The study includes outpatient infants who meet specific clinical criteria and excludes those requiring hospitalization or oxygen therapy. Participation lasts at least 21 days with regular follow-up calls to track symptom resolution and overall health.

This research investigates the impact of an early inhaled sedation strategy using Isoflurane delivered by an ANACONDA132; system compared to a conventional intravenous sedation method in intensive care patients who require invasive mechanical ventilation. The study focuses on preventing delirium, a common and serious complication in ventilated patients, by exploring sedation approaches in a Phase 3 clinical trial setting. Delirium is linked to worsened outcomes, including longer ventilation and hospital stays, and potential long-term cognitive effects. Participants receive either sedation through inhaled Isoflurane combined with analgesic drugs or conventional intravenous sedation with propofol and analgesics. Both groups use nurse-driven analgesia protocols including pain assessment scores and various pain management options such as opioids and non-opioid adjuncts. Sedation starts early, either at rapid sequence induction if intubated in intensive care or upon admission if pre-hospital intubation occurred. Throughout the study, patients are monitored for the occurrence of delirium within 28 days. Researchers assess comfort, safety, sedation effectiveness, and other clinical outcomes. Consent is obtained from patients or relatives, and sedation and analgesia are carefully managed using standardized protocols. The study excludes patients with certain neurological conditions, severe respiratory distress, and other specific criteria to ensure safety and reliable assessment of the sedation strategies.

Researchers are studying the impact of a prevention program called PREVENTURE on vulnerable teenagers aged 14 to 17 who have experimented with alcohol at least once. The study focuses on adolescents in Brittany, where alcohol use and episodes of heavy drinking are common. The trial aims to evaluate how well the PREVENTURE program reduces risky alcohol use compared to routine care, addressing the lack of effective primary prevention strategies for addictive behaviors in youth. Participants are randomly assigned to one of two groups based on their personality risk factors identified by the Substance Use Risk Profile Scale (SURPS). One group receives the PREVENTURE program, which includes two sessions of 90 minutes each, along with routine care. The control group receives routine care only. The SURPS questionnaire assesses four personality traits linked to substance misuse: impulsivity, sensation seeking, anxiety sensitivity, and hopelessness. Throughout the study, researchers will assess alcohol use at 6 months, focusing on episodes of intensive punctual alcohol consumption. Participants complete the SURPS questionnaire at enrollment. The study involves informed consent from both parents and teenagers, and requires access to the internet and a device such as a computer, tablet, or phone. The trial monitors adherence to the intervention and routine care to understand the program's effectiveness in preventing alcohol misuse among at-risk adolescents.

Long-term corticosteroid therapy is commonly used for various medical conditions but can cause significant side effects such as bone, metabolic, and infectious problems. This study evaluates a nurse-led prevention program designed to reduce these adverse events and improve quality of life in adults starting long-term corticosteroid treatment. The study excludes patients with cancer-related corticosteroid use, severe kidney failure, and organ transplants. Participants are randomly assigned to either a nurse-led prevention group or a standard care group. The nurse-led program includes educational videos about corticosteroid side effects, individual nurse interviews, dietitian consultations, personalized preventive advice sheets for patients and doctors, and follow-up phone calls at 12, 24, and 36 weeks. The standard care group receives a general prevention summary sheet along with usual medical care. All participants undergo clinical evaluations, blood tests, bone density scans, and quality of life assessments at the start and after 52 weeks. Corticosteroid use is tracked in a dedicated notebook throughout the year. The main outcome is measured by the glucocorticoid toxicity index at one year, assessed by a blinded independent physician to determine the program's effectiveness in reducing corticosteroid-related complications.

Researchers are evaluating the impact of electronic monitoring on patient compliance in managing hemopathies, blood-related cancers. As treatment has evolved with new drugs like CAR T-cells, immunotherapy, and targeted therapies, outpatient care and oral therapies have become more common. However, oral treatments may cause side effects related to the disease, treatment toxicity, or other health conditions, which can lead to treatment interruption. Detecting and managing these side effects in real time is important to ensure patients follow their prescribed treatments correctly and maintain safety and quality of life. The study compares two follow-up methods for patients starting oral therapy for hemopathies: standard follow-up and follow-up using a digital telemonitoring app called Cureety. Cureety is designed to help cancer patients report side effects themselves and support medical teams alongside usual care. Patients may also receive intravenous treatments as recommended, alongside oral therapies. The study focuses on patients expected to be on oral therapy for more than six months. Participants will be monitored over time with assessments at one, three, and six months to track treatment adherence and side effects. Researchers will evaluate how well patients follow their medication schedules and how electronic monitoring compares to standard care in detecting side effects early. The study includes social security-affiliated adults starting long-term oral therapy for hemopathies and requires patients to have internet and phone access for participation.